Telix Pharmaceuticals (NASDAQ:TLX) Receives Outperform Rating from Wedbush

Key Points

• Wedbush reaffirmed its “Outperform” rating on Telix Pharmaceuticals with a $22 price target, implying approximately 94.9% upside from the prior close.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $20.40; ratings include one Strong Buy, four Buys, and two Holds.
• Telix shares opened at $11.29, compared with a 52-week range of $6.28 to $12.48, while several institutional investors recently increased or initiated positions.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "outperform" rating reaffirmed by investment analysts at Wedbush in a research note issued to investors on Monday, Benzinga reports. They presently have a $22.00 price objective on the stock. Wedbush's price target indicates a potential upside of 94.86% from the company's previous close.

Several other equities research analysts also recently weighed in on the stock. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, September 2nd. Citigroup reiterated a "buy" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Weiss Ratings upgraded Telix Pharmaceuticals from a "sell (d)" rating to a "hold (c-)" rating in a research note on Friday, August 21st. Finally, Royal Bank Of Canada lowered Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $20.40.

Telix Pharmaceuticals Stock Performance

Shares of Telix Pharmaceuticals stock opened at $11.29 on Monday. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. The firm's 50 day moving average price is $11.23 and its 200-day moving average price is $10.16. Telix Pharmaceuticals has a 52-week low of $6.28 and a 52-week high of $12.48.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Rhumbline Advisers increased its stake in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock worth $25,000 after acquiring an additional 1,392 shares during the period. Bank of America Corp DE lifted its position in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company's stock valued at $96,000 after purchasing an additional 8,423 shares during the period. XTX Topco Ltd acquired a new position in Telix Pharmaceuticals during the fourth quarter valued at $89,000. XY Capital Ltd purchased a new stake in Telix Pharmaceuticals in the first quarter valued at $120,000. Finally, IHT Wealth Management LLC purchased a new stake in Telix Pharmaceuticals in the second quarter valued at $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company's commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.